A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations

被引:3
|
作者
Kobayashi, Hiroaki [1 ]
Kosaka, Takeo [1 ]
Nakamura, Kohei [2 ]
Shojo, Kazunori [1 ]
Hongo, Hiroshi [1 ]
Mikami, Shuji [3 ]
Nishihara, Hiroshi [2 ]
Oya, Mototsugu [1 ]
机构
[1] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan
[2] Keio Univ, Keio Canc Ctr, Genom Unit, Sch Med, Tokyo, Japan
[3] Keio Univ, Div Diagnost Pathol, Sch Med, Tokyo, Japan
关键词
Ductal adenocarcinoma; Neuroendocrine prostate cancer; Next-generation sequencing; Case report; CANCER; DIFFERENTIATION;
D O I
10.1186/s12920-021-01093-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Ductal adenocarcinoma and neuroendocrine cancer are rare subtypes of prostate cancer with poor prognosis and limited therapeutic options. We present the first case of ductal adenocarcinoma having a neuroendocrine phenotype. Case presentation A 63-year-old man presented with gross hematuria and urinary retention, and his serum prostate-specific antigen level was 4.58 ng/mL. We performed transurethral resection of the prostate, and the diagnosis was ductal adenocarcinoma with a Gleason score of 5 + 4 for acinar adenocarcinoma. Magnetic resonance imaging showed local invasion of left lobe of the prostate and bone metastasis of the left trochanteric section of the femur. Multidisciplinary treatments such as androgen deprivation therapy, chemoradiation therapy, and surgery for metastatic lesions have led to long-term survival. Since next-generation sequencing revealed PTEN and RB1 co-loss and TP53 mutations, we re-evaluated the immunohistochemistry and he was found to be positive for synaptophysin. Conclusions This is the first Japanese case of ductal adenocarcinoma with a neuroendocrine phenotype. Genetic analysis may help not only guide the therapeutic strategies, but also sometimes with the diagnosis.
引用
下载
收藏
页数:5
相关论文
共 50 条
  • [1] A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations
    Hiroaki Kobayashi
    Takeo Kosaka
    Kohei Nakamura
    Kazunori Shojo
    Hiroshi Hongo
    Shuji Mikami
    Hiroshi Nishihara
    Mototsugu Oya
    BMC Medical Genomics, 14
  • [2] Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer
    Humid, Anis A.
    Gray, Kathryn P.
    Shaw, Grace
    MacConaill, Laura E.
    Evan, Carolyn
    Bernard, Brandon
    Loda, Massimo
    Corcoran, Niall M.
    Van Allen, Eliezer M.
    Choudhury, Atish D.
    Sweeney, Christopher J.
    EUROPEAN UROLOGY, 2019, 76 (01) : 89 - 97
  • [3] TP53 and RB1 alterations promote reprogramming and antiandrogen resistance in advanced prostate cancer
    Mu, Ping
    Cao, Zhen
    Hoover, Elizabeth
    Wongvipat, John
    Huang, Chun-Hao
    Karthaus, Wouter
    Abida, Wassim
    De Stanchina, Elise
    Sawyers, Charles
    CANCER RESEARCH, 2015, 75
  • [4] Genetic Alterations of Both MEN1/ATRX and TP53/RB1 in Pancreatic Neuroendocrine Neoplasms
    Zhang, Ming-Yi
    He, Du
    Zhang, Shuang
    Liu, Ji-Yan
    PANCREAS, 2022, 51 (06) : e91 - e93
  • [5] Notch signaling and Tp53/RB1 pathway in pulmonary neuroendocrine tumorigenesis
    Ito, Takaaki
    Matsuo, Akira
    Hassan, Wael Abdo
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (02) : 213 - 219
  • [6] Chromosomal imbalances, and immunohistochemical loss of heterozygosity, expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate
    Bettendorf, Olaf
    Schmidt, Hartmut
    Staebler, Annette
    Grobholz, Rainer
    Heinecke, Achim
    Boecker, Werner
    Hertle, Lothar
    Semjonow, Axel
    GENES CHROMOSOMES & CANCER, 2008, 47 (07): : 565 - 572
  • [7] Concurrent somatic alterations of TP53 and RB1 in Chinese lung adenocarcinoma with or without EGFR mutations.
    Wang, Jun
    Chen, Gang
    Zhang, Bicheng
    Sun, Jianguo
    Liang, Jing
    Liu, Xiaolin
    Li, Yan
    Wang, Baocheng
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Locally recurrent prostate cancer with RB1/TP53 alterations successfully treated by salvage focal brachytherapy: a case report
    Komori, Takahiro
    Kosaka, Takeo
    Tanaka, Tomoki
    Watanabe, Keitaro
    Yasumizu, Yota
    Mikami, Shuji
    Oya, Mototsugu
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2023, 11 (04): : 339 - 343
  • [9] RB1 AND TP53 LOSS PROMOTES LINEAGE PLASTICITY IN PROSTATE CANCER
    不详
    CANCER DISCOVERY, 2017, 7 (03) : 244 - 244
  • [10] Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53
    Ueki, Hideto
    Jimbo, Naoe
    Terakawa, Tomoaki
    Hara, Takuto
    Tobe, Taisuke
    Hirata, Junichiro
    Wakita, Naoto
    Okamura, Yasuyoshi
    Suzuki, Kotaro
    Bando, Yukari
    Chiba, Koji
    Teishima, Jun
    Nakano, Yuzo
    Miyake, Hideaki
    PROSTATE, 2024,